De-Risking Production Of Complex Oral Solid Dosages: Considerations & Key Capabilities

As small-molecule therapies grow more potent and complex, oral solid dose (OSD) manufacturing is becoming increasingly risk-sensitive. Challenges such as poor API solubility, high-potency compound handling, and advanced formulation requirements introduce variability that can disrupt scale-up, delay timelines, and affect product quality.

Risk rarely stems from a single issue. Instead, it builds across development, technology transfer, and commercialization—often due to misalignment between formulation design and manufacturing realities. Addressing these risks requires early integration of formulation, process engineering, and analytical expertise to ensure scalability and consistency.

Manufacturers equipped with specialized technologies, containment infrastructure, and coordinated workflows can better manage complexity, maintain compliance, and support reliable production. Learn how aligning development decisions with long-term manufacturability can reduce variability, control costs, and create a smoother path to commercial success.